{"filing":{"accession_number":"0001213900-26-110869","cik":"0001611747","ticker":"SCNI","company_name":"Scinai Immunotherapeutics Ltd.","form":"6-K","filing_date":"2026-10-20","report_date":"2026-10-20","primary_document":"ea0309143-6k_scinai.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1611747/000121390026110869/ea0309143-6k_scinai.htm"},"events":[{"id":36337,"run_id":33501,"accession_number":"0001213900-26-110869","anchor_item_number":"EX-99.1","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.6,"summary":"This press release discloses multiple material events: (1) a new CDMO agreement worth ~$5.1 million in committed base fees plus ~$5.85 million in potential future work, representing a significant expansion of contracted business; (2) a completed financing raising ~$5.3 million in net proceeds through a SEPA drawdown and private placement; and (3) an extended operating runway to late 2027, potentially into Q3 2028. While the CDMO agreement is operational/contractual and the financing is financial (dilutive equity issuance), the disclosure bundles these as an integrated strategic announcement. The CDMO agreement does not fit cleanly into `ma_activity` (not an acquisition or merger), and the financing, though involving equity issuance, is presented as a capital-raising event supporting operations rather than a discrete `dilutive_issuance`. The combination of new customer contracts, extended runway, and capital raise is material to investor assessment but does not fit neatly into a single domain-specific category.","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-10-20","form":"6-K","submitted_at":null,"items":[{"id":40724,"accession_number":"0001213900-26-110869","item_number":"EX-99.1","item_title":"ea030914301ex99-1.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.6,"reasoning":"This press release discloses multiple material events: (1) a new CDMO agreement worth ~$5.1 million in committed base fees plus ~$5.85 million in potential future work, representing a significant expansion of contracted business; (2) a completed financing raising ~$5.3 million in net proceeds through a SEPA drawdown and private placement; and (3) an extended operating runway to late 2027, potentially into Q3 2028. While the CDMO agreement is operational/contractual and the financing is financial (dilutive equity issuance), the disclosure bundles these as an integrated strategic announcement. The CDMO agreement does not fit cleanly into `ma_activity` (not an acquisition or merger), and the financing, though involving equity issuance, is presented as a capital-raising event supporting operations rather than a discrete `dilutive_issuance`. The combination of new customer contracts, extended runway, and capital raise is material to investor assessment but does not fit neatly into a single domain-specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T14:10:39.478566+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40724,"accession_number":"0001213900-26-110869","item_number":"EX-99.1","item_title":"ea030914301ex99-1.htm","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.6,"reasoning":"This press release discloses multiple material events: (1) a new CDMO agreement worth ~$5.1 million in committed base fees plus ~$5.85 million in potential future work, representing a significant expansion of contracted business; (2) a completed financing raising ~$5.3 million in net proceeds through a SEPA drawdown and private placement; and (3) an extended operating runway to late 2027, potentially into Q3 2028. While the CDMO agreement is operational/contractual and the financing is financial (dilutive equity issuance), the disclosure bundles these as an integrated strategic announcement. The CDMO agreement does not fit cleanly into `ma_activity` (not an acquisition or merger), and the financing, though involving equity issuance, is presented as a capital-raising event supporting operations rather than a discrete `dilutive_issuance`. The combination of new customer contracts, extended runway, and capital raise is material to investor assessment but does not fit neatly into a single domain-specific category.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-20T14:10:39.478566+00:00","company_name":"Scinai Immunotherapeutics Ltd.","ticker":"SCNI","filing_date":"2026-10-20"}]}